Program Status
Active, not recruitingPhase
Phase 1Prior Immunotherapy Allowed
YesCRC-directed Trial
YesDrugs
BMS-986416, NivolumabTags
MSS/ MMRpComments
BMS-986416: anti LAG-3
Nivolumab: anti PD-1 (Opdivo), immunotherapy
Location | Location Status |
---|---|
United States | |
Local Institution - 0006 Atlanta, Georgia 30322 |
Active, not recruiting |
Local Institution - 0005 Baltimore, Maryland 21287 |
Active, not recruiting |
Local Institution - 0002 Hackensack, New Jersey 07601 |
Active, not recruiting |
Local Institution - 0013 Cleveland, Ohio 44106-1716 |
Active, not recruiting |
Local Institution - 0003 Pittsburgh, Pennsylvania 15232 |
Active, not recruiting |
Local Institution - 0004 Houston, Texas 77030 |
Active, not recruiting |
Argentina | |
Local Institution - 0021 Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ |
Active, not recruiting |
Local Institution - 0027 ABB, Ciudad Autónoma De Buenos Aires C1199ABB |
Active, not recruiting |
Local Institution - 0022 Caba, Ciudad Autónoma De Buenos Aires C1430EGF |
Active, not recruiting |
Belgium | |
Local Institution - 0043 Edegem, Antwerpen 2650 |
Active, not recruiting |
Local Institution - 0016 Gent, Oost-Vlaanderen 9000 |
Active, not recruiting |
Canada | |
Local Institution - 0009 Edmonton, Alberta T6X 1E8 |
Active, not recruiting |
Local Institution - 0008 Toronto, Ontario M5G 2M9 |
Active, not recruiting |
Local Institution - 0001 Montréal, Quebec H2X 3H8 |
Active, not recruiting |
Chile | |
Local Institution - 0025 Santiago, Región Metropolitana De Santiago 7500921 |
Active, not recruiting |
Local Institution - 0026 Santiago, Región Metropolitana De Santiago 7620002 |
Active, not recruiting |
Local Institution - 0024 Santiago, Región Metropolitana De Santiago 8420383 |
Active, not recruiting |
Japan | |
Local Institution - 0010 Chuo-ku, Tokyo 104-0045 |
Active, not recruiting |
Netherlands | |
Local Institution - 0020 Maastricht, Limburg 6229 HX |
Active, not recruiting |
Inclusion Criteria
Inclusion Criteria:
Participants with histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent select solid tumor
Eligible tumor types Non-small cell lung cancer (NSCLC), Urothelial carcinoma (UC), Squamous cell carcinoma of the head and neck (SCCHN), Hepatocellular carcinoma (HCC), Microsatellite-stable colorectal carcinoma (MSS CRC), or Pancreatic ductal adenocarcinoma (PDAC)
Resistant/refractory to or intolerant of existing standard therapies known to provide clinical benefit
Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)
Disease amenable to serial biopsy
Exclusion Criteria
Exclusion Criteria:
Uncontrolled or significant cardiovascular disease
Known connective tissue disease such as Marfan, Ehlers-Danlos, or Loeys-Dietz syndrome
Medical requirement for chronic anticoagulant or antiplatelet agents (except low-dose aspirin, which is permitted)
Other protocol-defined inclusion/exclusion criteria apply